ascopubs.org

Concordance of PD-L1 combined positive score (CPS) analysis between primary gastric cancer and matched peritoneal metastasis.

The role of determining HER2neu status in patients with gastric cancer. Advanced signet ring cell type gastroesophageal cancers in Latin American patients age 40 and below: A summary of one tertiary ...
ascopubs.org

PD-L1 Immunohistochemistry in Gastric Cancer: Comparison of Combined Positive Score and Tumor Area Positivity Across 28-8, 22C3, and SP263 Assays

The clinical application of PD-L1 immunohistochemistry (IHC) testing is complicated by the availability of multiple IHC assays, scoring algorithms, and cutoffs. This study assessed the analytical ...
MedPage Today

Immunotherapy Regimen Approved for Recurrent Ovarian Cancer

The FDA approved pembrolizumab (Keytruda) plus paclitaxel for recurrent ovarian cancers that express PD-L1, the agency ...
MedPage Today

Immunotherapy Combo Active in Advanced PD-L1-Negative HNSCC

A chemotherapy-free regimen combining the investigational therapy eftilagimod alpha with pembrolizumab (Keytruda) showed promising efficacy in a small cohort of patients with recurrent or metastatic ...
Seeking Alpha

FDA Approves KEYTRUDA® (pembrolizumab) for PD-L1+ Resectable Locally Advanced Head & Neck Squamous Cell Carcinoma as Neoadjuvant Treatment, Continued as Adjuvant Treatment ...

Approval introduces the first perioperative anti-PD-1 treatment regimen for adults with resectable locally advanced head and neck squamous cell carcinoma whose tumors express PD-L1 (CPS ≥1) The ...